FDA Pulls Sotrovimab EUA In More States, Territories As BA.2 Takes Over

By Beth Wang / March 31, 2022 at 12:02 PM
FDA on Wednesday (March 30) yanked emergency use authorization for GlaxoSmithKline’s COVID-19 monoclonal antibody sotrovimab in another 20 states and territories, meaning the drug is now off limits for use against coronavirus in a total of 30 states and territories where the BA.2 subvariant of Omicron has become the dominant coronavirus strain. The announcement comes as the U.S. government runs out of supply and money for COVID-19 therapies and vaccines, and as the Biden administration pushes Congress to provide immediate...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.